SEC Form 4 · accession 0001140361-15-027438

OncoMed Pharmaceuticals Inc · OMED

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — SVP & Chief Medical Officer

Period of report

Jul 10, 2015

Accepted (ET)

Jul 13, 2015 · 5:28 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001302573

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock^F2	Jul 10, 2015	M	2,500	$4.56	A	24,877	D
Common Stock^F2	Jul 10, 2015	S	2,500	$20.13	D	22,377	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Stock Option (Right to Buy)^F3	$4.56	Jul 10, 2015	M	2,500	D	—	Oct 24, 2021	Common Stock	2,500	153,937	D

F1Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on June 5, 2015.
F2Includes 20,000 restricted stock units. The Reporting Person is entitled to receive one (1) share of common stock for each one (1) restricted stock unit.
F3The option was immediately exercisable in full on October 24, 2011; however, the shares vest pursuant to the following schedule: Twenty Percent (20%) of the shares subject to the option vest on the first anniversary measured from October 1, 2011 (the "Vesting Commencement Date") and the remaining shares subject to the option vest in 48 successive, equal monthly installments thereafter on each monthly anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date.